GLP-1 discontinuation triggers 60-70% weight regain within 12 months across STEP and SURMOUNT extensions

Recent analyses of the STEP 1 trial extension and SURMOUNT-1 off-treatment follow-up confirm rapid reversal. Participants who discontinued semaglutide regained a mean 11.6 kg of the 17.3 kg lost, with systolic blood pressure and HbA1c returning toward baseline within 52 weeks. Tirzepatide data show a parallel pattern, with 60% of weight restored by week 48 post-cessation. These rebounds occur because the drugs suppress appetite via GLP-1 and GIP receptor agonism; once cleared, caloric intake rises without sustained behavioral scaffolding.

The pattern mirrors earlier yo-yo cycles but at population scale. More than 1 billion adults live with obesity, and current prescribing favors short-term use due to cost, supply limits, and side-effect burden. Health-system modeling indicates each cycle adds incremental cardiovascular events and repeat clinic visits. Observational cohorts in the UK and US already record 35-40% of initiators stopping within 18 months, setting conditions for repeated regain-loss loops that erode muscle mass and metabolic adaptation.

Long-term adherence data remain sparse. No large RCT has tested whether intensive lifestyle programs started during the GLP-1 window reduce post-discontinuation regain below 30%. Until such trials report, the medicines function as a temporary metabolic reset rather than a durable cure, shifting costs downstream to payers and primary care.

Next studies must track real-world cycling rates and composite outcomes over five years, incorporating muscle-preserving interventions and cost-effectiveness thresholds.